Answers are grounded in this paper and cite their sources.
Experimental compounds reduce IL-19 secretion in keratinocytes, suggesting new psoriasis therapies.
Psoriasis is a chronic inflammatory disorder characterized by skin inflammation and hyperproliferation due to abnormal differentiation of basal keratinocytes. The etiology is unclear, but psoriasis has been described as a prototypic Th17-mediated disease. Interleukin-19 (IL-19) is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis, and IL-19 production is induced in keratinocytes by IL-17A. However, the therapeutic applications of IL-19 for human disease have yet to be developed. We synthesized 24 new kinds of side-chain fluorinated 2-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 analogues based on the MART-10 and MART-11 skeletons, and their suppressive effects on keratinocyte IL-19 secretion were assessed. Surprisingly, more than half of the analogues exhibited potent suppressive effects with much greater efficiency than calcipotriol, a commonly clinically used medicine for the treatment of psoriasis. Furthermore, one of the best analogues, 24F2-MART-10, was selected to study therapeutic effects on psoriasis model mice. We found that comparable efficacy was achieved using only one-fifth of the volume of calcipotriol, highlighting the superior therapeutic potency of 24F2-MART-10. Osteocalcin promoter transactivation activity of all 24 analogues was also tested.
No takes yet. Share an insight, caveat, or question.
Kawagoe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: